Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2005 Dec 1;15(23):5311-4. Epub 2005 Oct 3.

Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.

Author information

1
Department of Basic Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. Zhijian_lu@merck.com

Abstract

Efforts directed to identifying potent HIV protease inhibitors (PI) have yielded a class of compounds that are not only very active against wild-type (NL4-3) HIV virus but also very potent against a panel of PI-resistant viral isolates. Chemistry and biology are described.

PMID:
16203148
DOI:
10.1016/j.bmcl.2005.08.072
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center